By Monica Heger

This story was originally published July 26.

With commitments for the sequencing of 17,000 tumor genomes in hand and 40 projects already underway, the International Cancer Genome Consortium is ahead of schedule to sequence 25,000 cancer genomes from 50 different body sites by 2018.

In addition, new projects have been added, including two by Cancer Research UK for esophageal and prostate cancers, and a brain cancer project from Genome Canada.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.